VectorLogics Overview
- Founded
- 1999
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
VectorLogics General Information
Description
Developer of virus based cancer therapies and therapeutic vaccines for viral liver diseases. The company utilizes IBDV technology for research on Viral hepatitis and Hepatocellular carcinoma. The company commercializes products for Cancer Virotherapy, Cancer Vaccines, Prophylactic and Therapeutic Vaccines.
Contact Information
Primary Office
- 550 11th Street South
- Birmingham, AL 35294
- United States
+1 (301) 000-0000
VectorLogics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 23-Oct-2012 | Completed | ||||
| 10. Grant | 22-Jul-2009 | 00000 | Completed | |||
| 9. Grant | 17-Sep-2008 | 00000 | Completed | |||
| 8. Grant | 21-Feb-2008 | 00000 | Completed | |||
| 7. Grant | 01-Jan-2008 | 00000 | Completed | |||
| 6. Grant | 01-Jan-2007 | 00000 | Completed | |||
| 5. Grant | 01-Jan-2006 | 00000 | Completed | |||
| 4. Grant | 01-Jan-2002 | 00000 | Completed | |||
| 3. Grant | 01-Jan-2001 | $170K | Completed | |||
| 2. Grant | 01-Jan-1999 | $350K | Completed |
VectorLogics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Curiel Ph.D | Chief Scientific Officer & Founder |
VectorLogics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Greer Capital Advisors | Venture Capital | Minority | 000 0000 | 000000 0 |